Cinflumide is a cinnamamide derivative manufactured by Burroughs Wellcome Co. It is claimed to be a CNS voluntary muscle relaxant.

Osanetant (SR-142801) is a NK3 receptor antagonist, it has a higher affinity for human and guinea pig NK3 receptors than for rat NK3 receptors. Osanetant was under development for the treatment of schizophrenia and other Central Nervous System (CNS) disorders. It was developed by Sanofi-Aventis (formerly Sanofi-Synthelabo). Sanofi was originally investigating its potential use as a treatment for psychosis and anxiety. Following phase IIa clinical trials, osanetant entered phase IIb development in February 2001. In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.

Metazide (RO 2-4969), a isonicotinic acid hydrazide derivative, is a tuberculostatic agent. Metazid causes damage to the membrane of Mycobacterium tuberculosis, inhibits metabolic and oxidative processes, inhibits the synthesis of nucleic acids, inhibiting the proliferation of bacteria inside and outside the cell. It has been used in the treatment of all forms and localizations of active tuberculosis in adults and children

Mesulfamide is a synthetic antibacterial agent.

Tesimide is an isoquinolinedione derivative patented by Warner-Lambert Co. as anti-inflammatory agent.

Tetronasin is a furanone derivative patented by Imperial Chemical Industries Ltd. as antibiotic and feed additive for ruminants. Tetronasin acts as divalent antiporter that binds preferentially with Ca2+ or Mg2+ and inhibits anaerobic fungi and Gram-negative bacteria in vitro.

Thiambutosine is a carbanilide derivative patented by Imperial Chemical Industries Ltd. as the antituberculous agent. In vitro, the resistance of Mycobacterium tuberculosis H37Rv to Thiambutosine develops more slowly than resistance to streptomycin, p-aminosalicylic acid, or isoniazid. A sub-inhibiting concentration of Thiambutosine with either streptomycin or isoniazid considerably retards the emergence of strains resistant to these two agents.

Thiohexamide is a first-generation, cyclohexyl-containing sulfonylurea with antihyperglycemic activity. The hypoglycemogenic activity of thiohexamide was detected in fasting, stable diabetic subjects.

AZD1775 selectively targets and inhibits WEE1, a tyrosine kinase that phosphorylates cyclin-dependent kinase 1 (CDK1, CDC2) to inactivate the CDC2/cyclin B complex. Inhibition of WEE1 activity prevents the phosphorylation of CDC2 and impairs the G2 DNA damage checkpoint. This may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents. Current ongoing trials of AZD1775 include monotherapy and combination therapy with certain DNA damaging agents in solid tumors, ovarian tumors, gynaecological cancer, non-small cell lung cancer. AZD1775 is genotoxic, which is considered to be a result of its mechanism of action. Common serious adverse events (with chemotherapy) include: febrile neutropenia, neutropenia, thrombocytopenia.

Timegadine Is a quinolylguanidine derivative patented by Loevens Kemiske Fabrik Produktionsaktieselskab as an anti-arthritic agent. Timegadine acts as a potent, competitive inhibitor of cyclo-oxygenase and lipo-oxygenase. Timegadine significantly inhibits both the primary and secondary lesions of rats adjuvant arthritis when the treatment is initiated on the day of the disease induction and continues for 28 days. Timegadine is able specifically to prevent the development of the swelling of the non-injected paw until 28 days after the adjuvant injection when administered for 5 days prior to and 5 days after the induction of the disease, in analogy with the effect of cyclophosphamide. In clinical trials, Timegadine significantly improves both biochemical and clinical markers of disease activity, i.e. ESR, serum IgG and IgM, leukocyte and platelet counts, duration of morning stiffness, Ritchie index, number of swollen joints and pain. Timegadine treatment associated with gastrointestinal and allergic side effects.